International Isotopes INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Radnostix Inc. reported a significant decrease in revenue for Q2 2026, driven by product recalls and operational impacts, alongside an increased net loss, though key debt agreements were modified.
OQB
Radnostix Inc. reported a significant decrease in revenue for the first quarter of 2026, primarily due to voluntary product recalls and operational shutdowns, leading to a substantial net loss.
OQB
International Isotopes Inc. reported an increased net loss for Q3 2025, driven by supply chain disruptions and an FDA Official Action Indicated, despite strategic growth initiatives.
OQB
International Isotopes Inc. reported a reduced net loss and increased revenue for the second quarter and first half of 2025, driven by strong Nuclear Medicine Standards sales.
OQB
International Isotopes Inc. saw a 12% increase in revenue for Q1 2025, primarily driven by growth in its Nuclear Medicine Standards segment, while experiencing a net loss of $112,694.
OQB
10-Q: International Isotopes Inc. Reports Improved Q3 Results Driven by Theranostics and Cobalt Sales
International Isotopes Inc. saw a significant improvement in its third-quarter results, driven by increased sales in its Theranostics and Cobalt product segments, despite a global shortage impacting its Nuclear Medicine Standards business.
OQB
International Isotopes Inc. saw a slight overall revenue increase in Q2 2024, with growth in Theranostics and Cobalt products offset by a significant decline in Nuclear Medicine Standards due to a global isotope shortage.
OQB
International Isotopes Inc. experienced a slight decrease in revenue and a net loss for the first quarter of 2024, impacted by a global shortage of Cobalt-57 isotopes.